Drugs / CER-001
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials · 2 missed | ||||||
| Phase 2 | NCT02484378 | Aug 2015 → Nov 2016 | acute coronary syndrome | Cerenis Therapeutics, SA | Completed | Missed primary |
| Phase 2 | NCT01515241 | Jan → Apr 2012 | familial hypercholesterolemia | Cerenis Therapeutics, SA | Completed | No outcome recorded |
| Phase 2 | NCT01412034 | Nov 2011 → Oct 2013 | homozygous familial hypercholesterolemia | Cerenis Therapeutics, SA | Completed | No outcome recorded |
| Phase 2 | NCT01201837 | Mar 2011 → Oct 2012 | acute coronary syndrome | Cerenis Therapeutics, SA | Completed | Missed primary |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT02697136 | Dec 2015 → Oct 2018 | hypoalphalipoproteinemia | Cerenis Therapeutics, SA | Terminated | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CER-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01412034 ↗ |
| Modality | Protein / enzyme biologic | “an ApoA-I-based HDL mimetic” NCT01201837 ↗ |
| Route | Intravenous | “29 intravenous infusions” NCT02697136 ↗ |